DalsnaFinance

Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

Markets PR Newswire By PR Newswire 22 Jun 2026 11:00 1 min read
Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets...

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.